Stark C, et al. - Given the approval of onabotulinumtoxinA (BOTOX, Allergan plc, Dublin, Ireland) for the preventive treatment of headaches in adult patients with chronic migraine (CM) in Australia by the country’s reimbursement mechanism for medicines, the Pharmaceutical Benefits Scheme (PBS), researchers sought to present the first focused report assessing real-world evidence of onabotulinumtoxinA treatment via the PBS in Australian clinics. From 7 private neurology practices in Australia who, beginning in March 2014, the medical records of 211 adults with insufficiently controlled CM who received PBS-subsidized onabotulinumtoxinA per product labeling were reviewed. The patients had a mean of 25.2 (5.3) monthly headache days at baseline. Clinical evidence gained supports the consistent efficacy of onabotulinumtoxinA for the treatment of CM in Australia. The therapy resulted in reductions in migraine days, severe headache days, and HIT-6 scores from baseline.